Ovarian Cancer is the fifth leading cause of death in women in the United States and the most common cause of death in women with gynaecological malignancies in most Western countries. Despite the significant advances in surgery, chemotherapy and radiotherapy, the resulting overall 5-year survival is about 40-50% [1]. In addition, millions of women remain fearful and concerned about being diagnosed with this too often fatal disease. While early detection improves the chances that ovarian cancer can be treated successfully, early cancers of the ovaries rarely cause symptoms that women would notice, or the symptoms are mistaken for menopausal ailments or intestinal illness. As a result, almost 75% of women with ovarian cancer are not diagnosed until the disease is advanced in stage with only 15-20% chances of reaching 5-year survival. Investigative efforts for the new millennium involve the areas of basic science and translational research, genetic susceptibility and prevention, diagnostic imaging, screening and diagnosis and, finally, therapy. Unfortunately, at present, results of treatment are still far from optimal. Integration of surgery with chemotherapy are crucial in the treatment of ovarian cancer and the recommended treatment strategy for patients with advanced ovarian cancer is radical cytoreductive surgery followed by 6 cycles of platinum-based combination chemotherapy [2]. The role of whole-abdominal radiation therapy in the treatment of ovarian cancer is still controversial. In particular, evidence that radiation therapy is curative in patients with advanced disease is lacking while severe toxicity is reported [3]. Critics of this modality have argued that the dose of radiation that can be safely delivered is low and unlikely to eradicate more than microscopic disease. Despite the fact that during the last two decades the cytoreductive ability of gynaecological oncologists has increased and an higher response rate to platinum-based chemotherapy can be obtained, the state of the art treatment fails to cure the vast majority of patients with advanced disease. In order to minimise the tumour burden before chemotherapy, cytoreductive (or debulking) surgery is usually performed upfront. Possible benefits from upfront cytoreductive surgery include: (a) improvement of tumour response to further therapy due to improved tumour perfusion and increased growth fraction. Smaller tumour masses require fewer cycles of chemotherapy with less chance of induced drug-resistance. Clones of phenotypically resistant cells may be removed also; (b) immediate treatment, or prevention of complications arising from tumour masses, i.e. bowel obstruction and ascites; (c) enhancement of the immunological competence of the patient. The immunogenicity of ovarian cancer has been demonstrated in vivo and cytoreduction may help the patient to mobilise her own immune response to the cancer [4]; (d) psychological benefit to the patient of knowing that the tumour bulk has been removed [5]. Several non randomised studies showed improved survival of patients with less than 1 cm diameter of residual tumour after primary surgery, as compared with patients with larger lesions. In a case-control study of patients with minimal residual disease, . Eisenkop et al. reported a longer survival for patients whose small lesions were completely resected rather than for those patients whose similar lesions were not completely removed [6]. Conversely, both Hoskins [7] and Hacker [8] reported that, despite optimal cytoreduction, the survival of patients with large intra-abdominal metastases before resection was significantly worse than that observed in patients with initially small intra-abdominal lesions. These observations suggested that intrinsic tumour factors are of prognostic importance in addition to residual disease after cytoreduction and also raised the question of whether cytoreduction has a significant effect on survival among patients with the same size tumours and the same intrinsic prognostic factors. Moreover, the problem still under debate is whether the observed survival benefits for cytoreduced patients are a function of surgical skill, tumour biology or both.
Read full abstract